Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2020

View Archived Issues

BMS details discovery and preclinical study of pulmonary fibrosis candidate BMS-986278

Blood substitution therapy expands therapeutic time window for stroke

iBET you I can kill those metastases

Elite controller achieves none-in-a-billion status

Efficacy and mechanism of action of novel DNA gyrase inhibitors against mycobacteria

Preclinical results suggest erectile dysfunction drugs can be repurposed to treat osteoporosis

FDA clears IND for global phase II study of CS-1001 for relapsed or refractory ENKTL

Cyprium reports topline clinical data for CUTX-101 in Menkes disease

Janssen Biotech patents DHODH inhibitors

U.S. researchers disclose new bacterial MenE inhibitiors

Skyhawk Therapeutics identifies small molecule splicing modulators for cancer

FDA expands EUA for Veklury to include hospitalized patients with mild or moderate COVID-19

Canwell Biotech synthesizes new TLR agonists

Taisho Pharmaceutical discloses new 20-HETE synthase inhibitors

Data presented on PF-05221304 and PF-06865571 coadministration in NAFLD patients

IIIM-290 development for treating pancreatic cancer advances into the clinic

TRILOGY 2 study of CaPre in severe hypertriglyceridemia does not meet primary endpoint

Akari details plans to develop nomacopan for COVID-19 pneumonia

Can-Fite's IND for phase II study of piclidenoson to treat COVID-19 cleared by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...